The Erythropoietin/Erythropoietin Receptor Signaling Pathway Promotes Growth and Invasion Abilities in Human Renal Carcinoma Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wu, Pengjie ^a   Zhang, Ning ^b   Wang, Xi ^a   Zhang, Chi ^a   Li, Teng ^a   Ning, Xianghui ^a   Gong, Kan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; LENTIVIRUS VECTOR; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL ACTIVATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROPOIETIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

LENTIVIRUS;

EID: 84866478695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045122     Document Type: Article

References (32)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320.
2. Gallou C, Joly D, Mejean A, Staroz F, Martin N, et al. (1999) Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 13: 464-475.
3. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, et al. (1998) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268-269.
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
5. Miyauchi Y, Kato M, Tokunaga F, Iwai K, (2008) The COP9/signalosome increases the efficiency of von Hippel-Lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination. J Biol Chem 283: 16622-16631.
6. Krieg M, Haas R, Brauch H, Acker T, Flamme I, et al. (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19: 5435-5443.
7. Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin WG, et al. (1997) Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 51: 575-578.
8. Sinha S, Dutta S, Datta K, Ghosh AK, Mukhopadhyay D, (2009) Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia. J Biol Chem 284: 32610-32618.
9. Kourembanas S, Hannan RL, Faller DV, (1990) Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 86: 670-674.
10. Westenfelder C, Baranowski RL, (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657.
11. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW, (2006) Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339.
12. Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, et al. (2005) Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11: 1059-1064.
13. Gong K, Zhang N, Zhang Z, Na Y, (2006) Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther 5: 582-585.
14. Lombardero M, Kovacs K, Scheithauer BW, (2011) Erythropoietin: a hormone with multiple functions. Pathobiology 78: 41-53.
15. Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, et al. (2007) Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int 100: 291-4.
16. Wiesener MS, Münchenhagen P, Gläser M, Sobottka BA, Knaup KX, et al. (2007) Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int J Cancer 121: 2434-42.
17. Gong K, Zhang N, Zhang K, Na Y, (2010) The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and-2α in sporadic clear cell renal carcinoma. Int J Mol Med 26: 907-12.
18. Sacko O, Bouillot-Eimer S, Sesay M, Uro-Coste E, Roux FE, et al. (2010) Hemangioblastoma of the corpus callosum: A case report and review of the literature on its origin. Neurochirurgie 56: 382-5.
19. Vortmeyer AO, Frank S, Jeong SY, Yuan K, Ikejiri B, et al. (2003) Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 63: 7051-5.
20. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, et al. (2007) von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med 4: e60.
21. Chan CC, Chew EY, Shen D, Hackett J, Zhuang Z, (2005) Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis 11: 697-704.
22. Chan CC, Collins AB, Chew EY, (2007) Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review. Retina 27: 1-7.
23. Vogel TW, Brouwers FM, Lubensky IA, Vortmeyer AO, Weil RJ, et al. (2005) Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. J Clin Endocrinol Metab 90: 3747-51.
24. Vogel TW, Vortmeyer AO, Lubensky IA, Lee YS, Furuta M, et al. (2005) Coexpression of erythropoietin and its receptor in endolymphatic sac tumors. J Neurosurg 103: 284-8.
25. Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, et al. (2009) RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 174: 1504-1514.
26. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, et al. (2010) Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18: 423-435.
27. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, et al. (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23: 1797-1805.
28. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, et al. (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029.
29. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, et al. (2012) Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 31: 1649-60.
30. Sakamoto H, Kitamura T, Yoshimura A, (2000) Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells. J Biol Chem 275: 35857-62.
31. Um M, Lodish HF, (2006) Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem 281: 5648-56.
32. Rini BI, Atkins MB. (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000. Establishment and characterization of colon carcinoma and renal cell carcinoma primary cultures.